Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

However, he disagrees with "a lot" of other points, like spending and acquisitions, and calls the Pfizer-BioNTech (BNTX) deal ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...